November 22, 2017 06:57 AM EST
R&D

#ASH17: Late break­er from Ab­b­Vie, Roche high­lights a block­buster break­out op­por­tu­ni­ty for Ven­clex­ta in CLL

John Carroll

Editor & Founder

When Ab­b­Vie $AB­BV and Roche $RHH­BY won ap­proval for Ven­clex­ta (vene­to­clax) back in the spring of 2016 as a new treat­ment for chron­ic lym­pho­cyt­ic leukemia …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

A service from the Financial Times